GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells

Zhu, Zhen; Shen, Huan; Xu, Jialin; Zheng, Fang; Wo, Guanqun; Ma, Yihui; Yang, Kai; Wang, Yalin; Yu, Qiang; Tang, Jinhai

doi:10.1016/j.drup.2023.100974

Cited by 13 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was innovative in demonstrating a predictor of SD in response to neoadjuvant chemotherapy. The TP53 polymorphism at codon 72 may be a predictor of resistance to chemotherapy, just as GATA3 is a predictor of resistance to doxorubicin in luminal tumors by decreasing apoptosis-inducing caspase 3 [45]. Unlike GATA3, codon 72 is a factor independent of the immunohistochemical subtype, which makes our study even more important [45].…”

Section: Discussionmentioning

confidence: 99%

<i>TP53</i> Gene Polymorphism at Codon 72 as a Response Predictor for Neoadjuvant Chemotherapy

Vieira,

Pesquero,

Nazário

2024

Breast Care

View full text Add to dashboard Cite

Introduction: Breast cancer is one of the most prevalent cancers in women worldwide and neoadjuvant chemotherapy is a favored method for achieving pathologic complete response (pCR). The TP53 gene is involved in inducing the response to chemotherapy drugs. Objectives: The present study sought to correlate polymorphism variants at codon 72 with pathologic complete response to neoadjuvant chemotherapy. Casuistry and Methods: The study was conducted in the state of Sergipe, in Northeastern Brazil. A total of 206 patients with a histopathological diagnosis of breast cancer who underwent neoadjuvant chemotherapy from 2019 to 2022 were included. DNA samples were collected for the evaluation of TP53 polymorphism at codon 72. A prospective evaluation of the cases was conducted to verify the surgical pathologic response after chemotherapy; the response evaluation criteria in solid tumors were used (RECIST). The study was approved by the University of São Paulo Ethics and Research Committee. Results: Of the 168 patients, 44.6% were Arg72Arg, 17.3% Pro72Pro, and 38.0% Arg72Pro; pCR was achieved in 21.4% of the patients; 10.1% had progressive disease, 13.7% stable disease, and 54.2% had a partial pathologic response. The only predictor of pCR in multivariate regression was immunohistochemistry (p < 0.001). In the multivariate analysis, Arg72Pro and Pro72Pro increased the odds of the patient evolve with stable disease.This study was innovative in demonstrating a predictor of stable disease in response to neoadjuvant chemotherapy Conclusion: TP53 polymorphism at codon 72 is not a predictor of pathologic complete response, but it can be a predictor of stable disease.

show abstract

Section: Discussionmentioning

confidence: 99%

<i>TP53</i> Gene Polymorphism at Codon 72 as a Response Predictor for Neoadjuvant Chemotherapy

Vieira,

Pesquero,

Nazário

2024

Breast Care

View full text Add to dashboard Cite

show abstract

“…Many genetic, environmental, and lifestyle factors have a role in the onset and spread of BRCA [ 1 ]. Much research has been done over the years to identify the underlying causes of BRCA and to create efficient treatment plans [ [ 2 , 3 ]].…”

Section: Introductionmentioning

confidence: 99%

Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer

Xia,

Zhou

2024

Heliyon

View full text Add to dashboard Cite

“…Presently, the study of drug resistance often encompasses various aspects, including Bulk‐RNA, metabolomics and proteomics, such as YTHDF1 facilitates S‐phase entry, DNA replication and DNA damage repair, 5 senescent neutrophils‐derived exosomal piRNA‐17560 enhances the expression of fat mass and obesity‐associated protein (FTO), 6 expression of a SUMOylation‐deficient mutant MORC2 or administration of SUMO inhibitor, 7 reduction of miR‐1275, 8 GATA3 promotes cell viability by decreasing ferroptosis‐related gene CYB5R2 expression. 9 However, these conventional methods fail to accurately capture individual differences between cells and struggle to effectively detect and analyse crucial cellular subpopulations. scRNA‐seq technology enables the presentation of the expression profile of all genes in the entire genome at the single‐cell level.…”

Section: Introductionmentioning

confidence: 99%

Single‐cell transcriptome sequencing reveals SPP1‐CD44‐mediated macrophage–tumor cell interactions drive chemoresistance in TNBC

Liu,

Zhang,

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) is often considered one of the most aggressive subtypes of breast cancer, characterized by a high recurrence rate and low overall survival (OS). It is notorious for posing challenges related to drug resistance. While there has been progress in TNBC research, the mechanisms underlying chemotherapy resistance in TNBC remain largely elusive. We collect single‐cell RNA sequencing (scRNA‐seq) data from five TNBC patients susceptible to chemotherapy and five resistant cases. Comprehensive analyses involving copy number variation (CNV), pseudotime trajectory, cell–cell interactions, pseudospace analysis, as well as transcription factor and functional enrichment are conducted specifically on macrophages and malignant cells. Furthermore, we performed validation experiments on clinical samples using multiplex immunofluorescence. We identified a subset of SPP1+ macrophages that secrete SPP1 signals interacting with CD44 on malignant cell surfaces, potentially activating the PDE3B pathway within malignant cells via the integrin pathway, leading to chemotherapy resistance. The abnormally enhanced SPP1 signal between macrophages and malignant cells may serve as a factor promoting chemotherapy resistance in TNBC patients. Therefore, SPP1+ macrophages could potentially serve as a therapeutic target to reduce chemotherapy resistance.

show abstract

GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells

Cited by 13 publications

References 48 publications

<i>TP53</i> Gene Polymorphism at Codon 72 as a Response Predictor for Neoadjuvant Chemotherapy

<i>TP53</i> Gene Polymorphism at Codon 72 as a Response Predictor for Neoadjuvant Chemotherapy

Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer

Single‐cell transcriptome sequencing reveals SPP1‐CD44‐mediated macrophage–tumor cell interactions drive chemoresistance in TNBC

Contact Info

Product

Resources

About